Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05976321 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-279 in Adults With or Without Liver Damage
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05976321 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 27 participants.
The verdict
NCT05976321, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-279. The participants will need to stay at the clinic for 11 days.
Interventions
- DRUG TAK-279
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05976321
The ClinicalTrials.gov registry entry for NCT05976321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-279 is the first listed.
NCT05976321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05976321 about?
NCT05976321 is a clinical study titled "A Study of TAK-279 in Adults With or Without Liver Damage". The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-2...
What is the current status of trial NCT05976321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2023-09-22. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05976321?
The interventions under investigation include: TAK-279 (DRUG).
Who is sponsoring clinical trial NCT05976321?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.